Latest news with #Teleflex
Yahoo
5 days ago
- Business
- Yahoo
LeMaitre (LMAT) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market close. Here's what to expect. LeMaitre beat analysts' revenue expectations by 3.7% last quarter, reporting revenues of $59.87 million, up 12% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' organic revenue estimates but a miss of analysts' EPS estimates. Is LeMaitre a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting LeMaitre's revenue to grow 12.1% year on year to $62.58 million, in line with the 11.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.57 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LeMaitre has missed Wall Street's revenue estimates three times over the last two years. Looking at LeMaitre's peers in the surgical equipment & consumables - specialty segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Teleflex delivered year-on-year revenue growth of 2.3%, beating analysts' expectations by 1.3%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Teleflex traded up 1.7% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Teleflex's results here and Intuitive Surgical's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the surgical equipment & consumables - specialty stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. LeMaitre is down 2.3% during the same time and is heading into earnings with an average analyst price target of $104.50 (compared to the current share price of $81.04). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
5 days ago
- Business
- Yahoo
Teleflex Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
The quarterly results for Teleflex Incorporated (NYSE:TFX) were released last week, making it a good time to revisit its performance. It looks like a credible result overall - although revenues of US$781m were what the analysts expected, Teleflex surprised by delivering a (statutory) profit of US$2.77 per share, an impressive 46% above what was forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Teleflex after the latest results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 13 analysts covering Teleflex are now predicting revenues of US$3.32b in 2025. If met, this would reflect a meaningful 9.2% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to shoot up 83% to US$7.97. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.13b and earnings per share (EPS) of US$8.42 in 2025. So it's pretty clear consensus is mixed on Teleflex after the latest results; whilethe analysts lifted revenue numbers, they also administered a minor downgrade to per-share earnings expectations. See our latest analysis for Teleflex The analysts also cut Teleflex's price target 5.1% to US$142, implying that lower forecast earnings are expected to have a more negative impact than can be offset by the increase in revenue. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Teleflex, with the most bullish analyst valuing it at US$200 and the most bearish at US$120 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Teleflex's growth to accelerate, with the forecast 19% annualised growth to the end of 2025 ranking favourably alongside historical growth of 4.0% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.2% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Teleflex to grow faster than the wider industry. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Teleflex. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Teleflex's future valuation. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Teleflex analysts - going out to 2027, and you can see them free on our platform here. However, before you get too enthused, we've discovered 2 warning signs for Teleflex that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
17-07-2025
- Business
- Globe and Mail
Teleflex Announces Second Quarter 2025 Earnings Conference Call Information
WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 31, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit
Yahoo
17-07-2025
- Business
- Yahoo
Teleflex Announces Second Quarter 2025 Earnings Conference Call Information
WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 31, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Contacts: Teleflex Incorporated: Lawrence Keusch Vice President, Investor Relations and Strategy Development
India Gazette
05-07-2025
- Business
- India Gazette
Teleflex signs MoU with Fortis Hospitals in India to create a UroLift Center of Education
HT Syndication New Delhi [India], July 5: Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has signed a Memorandum of Understanding with Fortis Hospitals Bengaluru to create the UroLift Center of Education in India. Teleflex announced that 500 patients have been treated with its UroLift System in India and Fortis Hospitals is the first hospital to treat about 100 BPH patients with the UroLift System. The UroLift System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life. The UroLift System is the only leading BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue. The UroLift System provides rapid symptom relief and preserves sexual function. Typically, no catheter is required after the treatment. 'At Teleflex, we believe that education is the foundation of progress in healthcare. Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare Limited stated, 'The healthcare landscape continues to evolve, and more minimally invasive therapies continue to emerge. At Fortis, we always strive to offer superior technologies to our patients. This educational initiative in association with Teleflex is another testament to our commitment to quality patient care.' Dr. Mohan Keshavamurthy, Principal Director - Renal Sciences, Fortis Hospitals, Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice.' These training programs for the UroLift System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru. About the UroLift System The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years and above in India. In India, prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management (GR optional). The UroLift permanent implants, delivered during the procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction. Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines as well as an optional procedure for BPH management in Urological Society of India guidelines. More than 500,000 men have been treated with the UroLift System in select markets worldwide. Learn more at Rx only. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit References: 1. Speakman et al. 2014 BJUI International 2. Roehrborn, J Urology 2013 3. AUA BPH Guidelines 2003, 2020 4. Shore, Can J Urol 2014 5. Roehrborn, Can J Urol 2017 6. McVary, J Sex Med 2016 7. Rukstalis, Prostate Cancer and Prostatic Dis 2018 8. Management estimate based on product sales and average units per procedure 9. Urological Society of India BPH Guidelines, 2019 *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study. (ADVERTORIAL DISCLAIMER: The above press release has been provided by HT Syndication. ANI will not be responsible in any way for the content of the same)
